Intensity Therapeutics, Inc.INTSNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank100
3Y CAGR+95.5%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+95.5%/yr
Annual compound
Percentile
P100
Near historical high
vs 3Y Ago
7.5x
Strong expansion
Streak
2 yr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| 2024 | 119.31% |
| 2023 | -6.74% |
| 2022 | -12.37% |
| 2021 | 15.96% |
| 2020 | 13.82% |
| 2019 | 0.00% |